| Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure VG Florea, MY Henein, SD Anker, DP Francis, JS Chambers, ... European heart journal 21 (2), 146-153, 2000 | 107 | 2000 |
| Shuttle-walk test to assess chronic heart failure SD Keell, JS Chambers, DP Francis, DF Edwards, RH Stables The Lancet 352 (9129), 705, 1998 | 83 | 1998 |
| Contribution of peripheral chemoreceptors to ventilation and the effects of their suppression on exercise tolerance in chronic heart failure. TP Chua, PP Ponikowski, D Harrington, J Chambers, AJ Coats Heart 76 (6), 483-489, 1996 | 76 | 1996 |
| Dyspnoea and exercise intolerance during cardiopulmonary exercise testing in patients with univentricular heart: the effects of chronic hypoxaemia and Fontan procedure L Iserin, TP Chua, J Chambers, AJS Coats, J Somerville European heart journal 18 (8), 1350-1356, 1997 | 40 | 1997 |
| An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC) HS Pandha, A Protheroe, J Wylie, C Parker, J Chambers, S Bell, ... Journal of Clinical Oncology 26 (15_suppl), 14547-14547, 2008 | 31 | 2008 |
| Pulmonary response of normal human subjects to inhaled vasodilator substances SJ Brett, J Chambers, A Bush, M Rosenthal, TW Evans Clinical Science 95 (5), 621-627, 1998 | 21 | 1998 |
| Superiority of endothelin-1 over norepinephrine in exercise-induced alterations of the conduit artery tone of the non-exercised arm in patients with chronic heart failure M Yousufuddin, W Shamim, JS Chambers, M Henein, FR Amin, SD Anker, ... International journal of cardiology 73 (1), 15-25, 2000 | 17 | 2000 |
| A phase I study of daily BIBW 2992, an irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel JF Spicer, D Harris, J Ang, M Chau, S Vizor, M Shahidi, ... ANNALS OF ONCOLOGY 19, 157-158, 2008 | 6 | 2008 |
| Naloxegol for patients with cancer pain diagnosed with opioid induced constipation (OIC): NACASY observational study. A Davies, J Tack, A Fernandez, J Chambers Journal of Clinical Oncology 38 (ASCO abstract e19350), 2020 | 3 | 2020 |
| Phase-3 randomized trial of everolimus (RAD001) vs. placebo in advanced pancreatic NET (RADIANT-3) J Chambers, N Reed, W Mansoor, P Ross, A Grossman Regulatory Peptides 164 (1), 6-7, 2010 | 3 | 2010 |
| Similarities between exercise capacity and ventilation in patients with mitochondrial myopathy and chronic heart failure D Harrington, JS Chambers, SD Anker, J Morgan-Hughes, ... Journal of the American College of Cardiology 31 (2SA), 331A-331A, 1998 | 1 | 1998 |
| Real-life evaluation of budesonide/formoterol (DuoResp Spiromax®) for the management of asthma and COPD in the UK. JV Nicolas Roche, Hitcham Benhaddi, Marianka van der Toll, Jonathan Chambers ... European Respiratory Journal, 2017 | | 2017 |
| Afinitor UK particular patient supplies for advanced neuroendocrine tumours. JS Chambers Neuroendocrinology 94 (Suppl. 1), 13, 2011 | | 2011 |
| Preliminary Report of the Use of Everolimus in a Patient with Progressive Medullary Thyroid Carcinoma M Druce, K Maher, S Grozinsky-Glasberg, D Gross, J Chambers, ... | | 2010 |
| Everolimus (RAD001) compassionate supplies programme JS Chambers Regulatory Peptides 1 (164), 10, 2010 | | 2010 |
